Federated Hermes’s Lyell Immunopharma LYEL Stock Holding History

Federated Hermes’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-584	Closed	-$16.9K	–	2117
2024 Q2	$16.9K	Buy	584 +49	+9%	+$2.33K	﹤0.01%	1730
2024 Q1	$23.9K	Sell	535 -231	-30%	-$9.89K	﹤0.01%	1707
2023 Q4	$29.7K	Buy	766 +121	+19%	+$4.36K	﹤0.01%	1708
2023 Q3	$19K	Sell	645 -47	-7%	-$2.23K	﹤0.01%	1769
2023 Q2	$44K	Buy	+692	New	+$38.3K	﹤0.01%	1691
2023 Q1	–	Sell	-25,660	Closed	-$1.78M	–	2204
2022 Q4	$1.78M	Hold	25,660	–	–	﹤0.01%	948
2022 Q3	$3.76M	Hold	25,660	–	–	0.01%	736
2022 Q2	$3.35M	Hold	25,660	–	–	0.01%	791
2022 Q1	$2.59M	Buy	25,660 +15,385	+150%	+$1.86M	0.01%	960
2021 Q4	$1.59M	Sell	10,275 -15,675	-60%	-$3.5M	﹤0.01%	1114
2021 Q3	$7.68M	Sell	25,950 -3,462	-12%	-$1.04M	0.01%	714
2021 Q2	$9.55M	Buy	+29,412	New	+$9.65M	0.02%	676

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's LYEL Position: Q3 2024 in Review

Federated Hermes sold out of Lyell Immunopharma (LYEL) in Q3 2024, closing a stake of 584 shares — an estimated $16.9K sold.

Federated Hermes first reported a position in LYEL in Q2 2021 and held it in 12 quarters. The position peaked at $9.55M in Q2 2021. 117 funds tracked by Wall St. Rank hold LYEL as of Q3 2024.

Federated Hermes reported no remaining Lyell Immunopharma position as of Q3 2024 after selling out during the quarter.
Federated Hermes sold 584 Lyell Immunopharma shares in Q3 2024, an estimated $16.9K.
Federated Hermes first reported a position in Lyell Immunopharma in Q2 2021 and held it in 12 quarters.
Federated Hermes's Lyell Immunopharma position peaked at $9.55M in Q2 2021.
117 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2024.

Based on Federated Hermes's 13F filing for Q3 2024, filed 13 Nov 2024.